natgillin/translations-raw huggingface dataset:
Eli Lilly Nederland B.V., Papendorpseweg 83, 3528 BJ Utrecht, The Netherlands
Eli Lilly Nederland B.V, Papendorpseweg 83, 3528 BJ Utrecht, Nizozemska
Eli Lilly Nederland B.V., Papendorpseweg 83, 3528 BJ Utrecht, The Netherlands
Eli Lilly Nederland B.V., Papendorpseweg 83, 3528 BJ Utrecht , Nizozemska
Eli Lilly Nederland B.V., Papendorpseweg 83, 3528 BJ Utrecht, The Netherlands
Eli Lilly Nederland B.V., Papendorpseweg 83, 3528 BJ Utrecht, Nizozemska.
Eli Lilly Nederland B.V., Papendorpseweg 83, 3528 BJ Utrecht, The Netherlands.
Eli Lilly Nederland B.V. Papendorpseweg 83, 3528 BJ Utrecht, Nizozemska.
Eli Lilly Nederland B.V., Papendorpseweg 83, 3528 BJ Utrecht, The Netherlands.
Eli Lilly Nederland B.V., , Nizozemska
Eli Lilly Nederland B.V., Papendorpseweg 83, 3528 BJ Utrecht, The Netherlands.
Eli Lilly Nederland B.V., Papendorpseweg 83, 3528 BJ Utrecht , Nizozemska
Eli Lilly Nederland B.V., Papendorpseweg 83, 3528 BJ Utrecht, The Netherlands.
Eli Lilly Nederland B.V., Papendorpseweg 83, 3528 BJ Utrecht, Nizozemska
Eli Lilly Nederland B.V., Papendorpseweg 83, 3528 BJ Utrecht, The Netherlands.
Eli Lilly Nederland BV Papendorpseweg 83, 3528 BJ Utrecht, Nizozemska
Eli Lilly Nederland B.V., Papendorpseweg 83, 3528 BJ Utrecht, The Netherlands.
Eli Lilly Nederland BV., Papendorpseweg 83, 3528 BJ Utrecht, Nizozemska
Eli Lilly Nederland B.V., Papendorpseweg 83, 3528 BJ Utrecht,, The Netherlands
Eli Lilly Nederland B.V., Papendorpseweg 83, 3528 BJ Utrecht, Nizozemska
Eli Lilly Norge A.S. Tlf: + 47 22 88 18 00
Eli Lilly Holdings Limited atstovybė Tel. +370 (5) 2649600
Eli Lilly Regional Operations GmbH., Kölblgasse 8-10,
Eli Lilly Regional Operations GmbH, Kölblgasse 8-10,
Eli Lilly Regional Operations GmbH., Kölblgasse 8-10, 1030, Vienna, Austria.
Eli Lilly Regional Operations GmbH, Kölblgasse 8-10, 1030 Beč, Austrija.
Eli Lilly România S.R.L. Tel: + 40 21 4023000
Eli Lilly Nederland B.V. Tel: + 31-(0) 30 60 25 800
Eli Lilly S.A. Dunderrow Kinsale County Cork Ireland
Eli Lilly S.A. Dunderrow Kinsale County Cork Irska‌
Eli Lilly Sweden AB Tel: + 46 (0) 8 7378800
Eli Lilly and Company Limited Tel: +44 (0) 1256 315000
Eli Lilly Sweden AB Tel: + 46-(0) 8 7378800
Eli Lilly Sweden AB Tel: +46-(0) 8 737 88 00
Eli Lilly Sweden AB Tel: + 46-(0) 8 7378800
Eli Lilly Sweden AB Tel: +46-(0) 8 7378800
Eligible for efficacy analysis, n
Pogodni za analizu djelotvornosti, n
Eligible patients for these trials had chronic hepatitis C confirmed by a positive HCV- RNA polymerase chain reaction assay (PCR) (> 30 IU/mL), a liver biopsy consistent with a histological diagnosis of chronic hepatitis with no other cause for the chronic hepatitis, and abnormal serum ALT.
Bolesnici pogodni za ova ispitivanja imali su kronični hepatitis C potvrđen pozitivnim nalazom HCV-RNK pomoću testa lančane reakcije polimerazom (PCR) (>30 IU/ml), nalazom biopsije jetre koji je odgovarao patohistološkoj dijagnozi kroničnog hepatitisa bez nekog drugog mogućeg uzroka kroničnog hepatitisa i odstupanjem od normalnih vrijednosti ALT-a u serumu.
Eligible patients had persistent, recurrent or metastatic squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of the cervix which was not amenable to curative treatment with surgery and/or radiation therapy and who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor–targeted agents.
Bolesnice pogodne za uključivanje u ispitivanje imale su perzistentni, recidivirajući ili metastatski planocelularni karcinom, adenoplanocelularni karcinom ili adenokarcinom cerviksa koji nije odgovorio na kurativno liječenje kirurškim zahvatom i/ili radioterapijom i prethodno nisu bile liječene bevacizumabom ili drugim VEGF inhibitorima niti lijekovima koji djeluju na VEGF receptore.
Eligible patients had received chemotherapy for malignancy or had undergone hematopoietic stem-cell transplantation, and presented with neutropaenia (<500 cells/mm3 for 96 hours) and fever (>38.0°C) not responding to ≥96 hours of parenteral antibacterial therapy.
Odabrani bolesnici primali su kemoterapiju zbog maligne bolesti ili su im bile presađene krvotvorne matične stanice, a imali su neutropeniju (<500 stanica/mm3 tijekom 96 sati) i vrućicu (>38,0°C) koje nisu odgovarale na parenteralnu antibakterijsku terapiju koja je trajala ≥96 sati.
Eligible patients were randomised in a 1:1 ratio to receive either Empliciti in combination with lenalidomide and dexamethasone or lenalidomide and dexamethasone.
Bolesnici koji su zadovoljavali uvjete za sudjelovanje u ispitivanju randomizirani su u omjeru 1:1 za primanje lijeka Empliciti u kombinaciji s lenalidomidom i deksametazonom ili za primanje lenalidomida i deksametazona.
Eligible patients were randomized (1:1:1:1) to placebo or one of three fixed levodopa/carbidopa doses of 145 mg/36.25 mg,
Podobni bolesnici randomizirani su (1:1:1:1) u placebo ili u jednu od tri fiksne doze levodope/karbidope od
Eligible patients were randomized in a 2:1 ratio to receive either naloxegol 25 mg daily (qd) or usual care treatment for OIC for 52 weeks.
Bolesnici koji su mogli sudjelovati u ispitivanju randomizirani su u omjeru 2:1 za primanje ili naloksegola u dozi od 25 mg na dan ili standardnog liječenja za konstipaciju uzrokovanu primjenom opioida tijekom 52 tjedna.
Eliglustat is also contraindicated in patients who are CYP2D6 poor metabolisers taking a strong CYP3A inhibitor.
Eliglustat je također kontraindiciran u bolesnika koji su spori metabolizatori CYP2D6, a koji uzimaju jaki inhibitor CYP3A.
Eliglustat is contraindicated in patients who are CYP2D6 Intermediate Metabolisers or Extensive Metabolisers who are taking a strong or moderate CYP2D6 inhibitor concomitantly with a strong or moderate CYP3A inhibitor.
Eliglustat je kontraindiciran u bolesnika koji su intermedijarni metabolizatori ili ekstenzivni metabolizatori CYP2D6, a koji uzimaju jak ili umjeren inhibitor CYP2D6 istovremeno s jakim ili umjerenim inhibitorom CYP3A.
Eliglustat is extensively metabolized with high clearance, mainly by CYP2D6 and to a lesser extent CYP3A4.
Eliglustat se opsežno metabolizira uz visoki klirens, uglavnom putem CYP2D6 i u manjoj mjeri CYP3A4.
Eliglustat should not be used concomitantly with medicines that may have an impact on liver enzymes that play a role in the metabolism of eliglustat.
Eliglustat se ne smije koristiti istodobno s lijekovima koji mogu utjecati na jetrene enzime koji imaju ulogu u metabolizmu eliglustata.
Elimination
Farmakokinetička svojstva
Elimination
Izlučivanje
Elimination
Pušači
Elimination and half-Life
Eliminacija i poluvijek
Elimination appears monophasic with a half-life of about 4 hours after a single-subcutaneous dose to about 7 hours after repeated dosing.
Čini se da je eliminacija monofazna s poluvijekom od otprilike 4 sata nakon jednokratne supkutane doze do otprilike 7 sati nakon ponavljanog doziranja.
Elimination half-life (h)
Poluvijek eliminacije (h)
Elimination half-life is long – approximately 5.5 days.
Poluživot eliminacije je dugačak – približno 5,5 dana.
Elimination half-life is long – approximately 6.9 days.
Poluživot eliminacije je dugačak – približno 6,9 dana.
Elimination of A771726 is slowand characterised by an apparent clearance of about 31 ml/hr.
Eliminacija A771726 je spora i karakterizirana je prividnim klirensom od oko 31 ml/sat.
Elimination of ceftazidime and avibactam is decreased in patients with moderate or severe renal impairment.
Eliminacija ceftazidima i avibaktama smanjena je kod bolesnika s umjerenim ili teškim oštećenjem funkcije bubrega.
Elimination of fleas within 24 hours.
Uništavanje buha u roku od 24 sata.
Elimination of rivaroxaban from plasma occurs with terminal half-lives of 5 to 9 hours in young individuals, and with terminal half-lives of 11 to 13 hours in the elderly.
Eliminacija rivaroksabana iz plazme odvija se s poluvremenom od 5 do 9 sati kod mlađih pojedinaca, a 11 do 13 sati kod starijih.
Elimination of selexipag is predominantly via metabolism with a mean terminal half-life of 0.8–2.5 h.
Eliminacija seleksipaga se uglavnom odvija putem metabolizma sa srednjom vrijednošću terminalnog poluživota 0,8–2,5 sati.
Elimination of valdecoxib is by extensive hepatic metabolism involving multiple pathways, including cytochrome P 450 (CYP) 3A4 and CYP2C9 isoenzymes and glucuronidation (about 20%) of the sulphonamide moiety.
Valdekoksib se eliminira opsežnim metaboliziranjem u jetri pomoću brojnih metaboličkih puteva, uključujući izoenzime citokroma P450 (CYP) 3A4 i CYP2C9 i glukuronidaciju (oko 20%) sulfonamidnog dijela.
elimination pathway of
eliminacije telaprevira).
Elimination rate is markedly lower than in older children and adults, with an elimination half-life estimated at approximately 30 hours (16–43).
Brzina eliminacije je značajno niža u odnosu na izlučivanje u starije djece i odraslih, s procijenjenim poluvremenom eliminacije od približno 30 sati (16-43).
Elimination: After subcutaneous bolus administration, the mean terminal half-life t½ of somatropin is about 2.3 hours.
Eliminacija: Nakon supkutane bolus primjene, prosječni poluvijek t½ somatropina iznosio je 2,3 sata.
Elimination: Clearance of enfuvirtide after intravenous administration 90 mg was 1.4  0.28 l/h and the elimination half-life was 3.2  0.42 h.
Eliminacija: Klirens enfuvirtida nakon intravenske primjene doze od 90 mg bio je 1,4  0,28 l/h, a poluvrijeme eliminacije je iznosilo 3,2  0,42 h.
Elimination: entecavir is predominantly eliminated by the kidney with urinary recovery of unchanged drug at steady-state of about 75% of the dose.
Eliminacija: entekavir se uglavnom eliminira bubrezima, a u mokraći se može naći oko 75% doze u obliku neizmijenjenog lijeka pri stanju dinamičke ravnoteže.
Elimination: Erlotinib is excreted predominantly as metabolites via the faeces (>90%) with renal elimination accounting for only a small amount (approximately 9%) of an oral dose.
Eliminacija: Erlotinib se uglavnom izlučuje u obliku metabolita putem fecesa (>90%), dok se manji dio peroralne doze uklanja putem bubrega (otprilike 9%).
Elimination: Memantine is eliminated in a monoexponential manner with a terminal t½ of 60 to 100 hours.
Eliminacija: Memantin se eliminira monoeksponencijalno s terminalnim t½ od 60 do 100 sati.
Elimination: Memantine is eliminated in a monoexponential manner with a terminal t½ of 60 to100 hours.
Eliminacija: memantin se eliminira monoeksponencijalno s terminalnim t½ od 60 do 100 sati.
Eliquis (apixaban) is an oral anticoagulant acting by direct selective inhibition of factor Xa.
Eliquis (apiksaban) je oralni antikoagulans, koji djeluje izravnom selektivnom inhibicijom faktora Xa.
Eliquis (apixaban) Patient Alert Card
Eliquis (apiksaban)
Eliquis 2.5 mg film-coated tablets
Eliquis 2,5 mg filmom obložene tablete
Eliquis 2.5 mg film-coated tablets apixaban
Eliquis 2,5 mg filmom obložene tablete apiksaban
Eliquis 2.5 mg tablets apixaban
Eliquis 2,5 mg tablete apiksaban
Eliquis 5 mg film-coated tablets
Eliquis 5 mg filmom obložene tablete
Eliquis 5 mg film-coated tablets apixaban
Eliquis 5 mg filmom obložene tablete apiksaban
Eliquis 5 mg tablets apixaban
Eliquis 5 mg tablete apiksaban
Eliquis apixaban
Eliquis apiksaban
Eliquis contains lactose (a type of sugar).
Eliquis sadrži laktozu (jednu vrstu šećera).
Eliquis Eliquis
Eliquis
Eliquis helps to thin your blood.
Eliquis Vam pomaže razrijediti krv.
Eliquis is a medicine that contains the active substance apixaban.
Eliquis je lijek koji sadrži djelatnu tvar apiksaban.
Eliquis is not recommended as an alternative to unfractionated heparin in patients with pulmonary embolism who are haemodynamically unstable or may receive thrombolysis or pulmonary embolectomy since the safety and efficacy of apixaban have not been established in these clinical situations.
Eliquis se ne preporučuje kao alternativa nefrakcioniranom heparinu u bolesnika s plućnom embolijom koji su hemodinamski nestabilni ili kod kojih bi se mogla primijeniti tromboliza ili plućna embolektomija jer sigurnost i djelotvornost apiksabana nisu ustanovljene u tim kliničkim situacijama.
Eliquis is not recommended in children and adolescents under 18 years of age.
Eliquis se ne preporučuje za djecu i adolescente mlađe od 18 godina.
Eliquis is used in adults: to prevent a blood clot from forming in the heart in patients with an irregular heart beat (atrial fibrillation) and at least one additional risk factor.
U odraslih se Eliquis koristi: za sprječavanje nastanka krvnog ugruška u srcu u bolesnika s nepravilnim otkucajima srca (fibrilacija atrija) kod kojih postoji još barem jedan dodatan čimbenik rizika.
Eliquis is used to prevent venous thromboembolism (blood clots in the veins) in adults following a hip or knee replacement operation.
Eliquis se koristi za prevenciju venskih tromboembolijskih događaja (krvnih ugrušaka u venama) u odraslih bolesnika podvrgnutih kirurškom zahvatu zamjene kuka ili koljena.
Eliquis may increase the risk of bleeding.
Eliquis može povećati rizik od krvarenja.
Eliquis must not be used in patients who are actively bleeding, or who have liver disease which leads to problems with blood clotting and an increased risk of bleeding.
Eliquis se ne smije koristiti u bolesnika koji aktivno krvare ili koji imaju bolest jetre što rezultira problemima s grušanjem krvi i povećanim rizikom od krvarenja.
Eliquis should be discontinued at least 24 hours prior to elective surgery or invasive procedures with a low risk of bleeding.
Eliquis treba prestati primjenjivati barem 24 sata prije elektivnog kirurškog zahvata ili invazivnog postupka kod kojih postoji malen rizik od krvarenja.
Eliquis should be discontinued at least 48 hours prior to elective surgery or invasive procedures with a moderate or high risk of bleeding.
Eliquis treba prestati primjenjivati barem 48 sati prije elektivnog kirurškog zahvata ili invazivnog postupka kod kojih postoji umjeren ili visok rizik od krvarenja.
Eliquis should be restarted after the invasive procedure or surgical intervention as soon as possible provided the clinical situation allows and adequate haemostasis has been established (for cardioversion see section 4.2).
Eliquis se mora početi ponovno uzimati što je prije moguće nakon invazivnog postupka ili kirurškog zahvata, ako to dopušta klinička situacija i ako je uspostavljena adekvatna hemostaza (za kardioverziju, vidjeti dio 4.2).
Eliquis should be swallowed with water, with or without food.
Eliquis treba progutati s vodom, s hranom li bez nje.
Eliquis should be used with caution when coadministered with NSAIDs (including acetylsalicylic acid) because these medicinal products typically increase the bleeding risk.
Potreban je oprez kod istodobne primjene lijeka Eliquis s NSAIL-ima (uključujući acetilsalicilatnu kiselinu) jer oni obično povećavaju rizik od krvarenja.
Eliquis was also effective at treating deep vein thrombosis and pulmonary embolism and preventing their reoccurrence: in the treatment study, 2.3% of patients treated with Eliquis had a clotting event or died, compared with 2.7% of patients treated with enoxaparin plus warfarin, showing that Eliquis was as effective as the comparator treatment.
Eliquis je bio također djelotvoran u liječenju duboke venske tromboze i plućne embolije te u sprječavanju njihovog ponovnog nastajanja: u ispitivanju liječenja, 2,3% bolesnika liječenih lijekom Eliquis imalo je ugrušak ili je preminulo u usporedbi s 2,7% bolesnika liječenih enoksaparinom plus warfarinom, dokazano je da je Eliquis bio podjednako djelotvoran kao usporedno liječenje.
Eliquis was also shown to be effective in preventing strokes and arterial blood clots in patients with atrial fibrillation.
Eliquis se također pokazao djelotvornim u sprječavanju moždanih udara i krvnih ugrušaka u arterijama u bolesnika s fibrilacijom u arterijama.
Eliquis was effective at preventing blood clots in the veins following a hip or knee replacement.
Eliquis je bio djelotvoran u sprječavanju nastanka krvnih ugrušaka u venama nakon kirurškog zahvata zamjene kuka ili koljena.
Eliquis will be used with caution in patients with signs of altered liver function.
Eliquis će se primjenjivati uz oprez u bolesnika koji pokazuju znakove poremećaja jetrene funkcije
Eliquis will be used with caution in patients with signs of altered liver function.
Eliquis će se primjenjivati uz oprez u bolesnika koji pokazuju znakove poremećaja jetrene funkcije.
ELISA = enzyme-linked immunosorbent assay; GMT= geometric mean titre; N = number of subjects in the specific study group; PRNT = plaque reduction neutralisation test; SCR = seroconversion rate;
ELISA = enzimski imunotest; GMT= geometrijski prosjek titra; N = broj ispitanika u određenoj ispitivanoj skupini; PRNT = test neutralizacije redukcije plaka; SCR = stopa serokonverzije;
ELISA > 3.34 log2 IE50 %
ELISA > 3,34 log2 IE50
ELISA > 3.34 log2 IE50%*
ELISA > 3,34 log2 IE50
ELISA > 3.34 log2 IE50%**
ELISA > 3,34 log2 IE50
ellaOne can be taken at any time during the menstrual cycle.
ellaOne se smije uzeti bilo kada tijekom menstruacijskog ciklusa.
ellaOne contains lactose
ellaOne sadrži laktozu
ellaOne contains the substance ulipristal acetate which acts by modifying the activity of the natural hormone progesterone which is necessary for ovulation to occur.
ellaOne sadrži tvar ulipristalacetat koja mijenja aktivnost prirodnog hormona progesterona, koji je potreban kako bi došlo do ovulacije.
ellaOne does not interrupt an existing pregnancy.
ellaOne ne prekida postojeću trudnoću.
ellaOne does not prevent pregnancy in every case.
ellaOne ne sprječava trudnoću u svim slučajevima.
ellaOne inhibits or postpones ovulation (see section 5.1).
ellaOne sprječava ili odgađa ovulaciju (vidjeti dio 5.1).
ellaOne is a contraceptive intended to prevent pregnancy after unprotected sex or if your contraceptive method has failed.
ellaOne je kontraceptiv namijenjen sprječavanju trudnoće nakon nezaštićenog snošaja ili zatajenja kontracepcijske metode.
ellaOne is a contraceptive used to prevent a pregnancy from starting.
ellaOne je kontraceptiv koji sprječava da dođe do trudnoće.
ellaOne is an emergency contraceptive
ellaOne je hitni kontraceptiv
ellaOne is an emergency contraceptive that decreases pregnancy risk after unprotected intercourse but does not confer contraceptive protection for subsequent acts of intercourse.
ellaOne hitna je kontracepcija koja smanjuje rizik od trudnoće nakon nezaštićenog snošaja, ali ne štiti od začeća pri sljedećim snošajima.
ellaOne is for occasional use only.
ellaOne je samo za sporadičnu uporabu.
ellaOne is not intended for use during pregnancy and should not be taken by any woman suspected or known to be pregnant (see section 4.2).
ellaOne nije namijenjena za primjenu tijekom trudnoće i ne smiju je uzeti žene u kojih se sumnja ili se zna da su trudne (vidjeti dio 4.2).
ellaOne is not intended for use during pregnancy and should not be taken by any woman suspected or known to be pregnant.
ellaOne nije namijenjena uporabi tijekom trudnoće i ne smiju je uzimati žene koje sumnjaju ili znaju da su trudne.
ellaOne may make regular hormonal contraceptives, like pills and patches, temporarily less effective.
ellaOne može privremeno smanjiti djelotvornost redovnih hormonskih kontraceptiva kao što su kontracepcijske tablete i flasteri.
ellaOne will not affect your future fertility.
ellaOne neće utjecati na Vašu plodnost u budućnosti.
ELLIPTA 1 inhaler of 7 doses
ELLIPTA 1 inhalator sa 7 doza
Elliptical, blue, coated tablets debossed with “LILLY” and a numeric identicode “4415”.
Eliptične, plave, obložene tablete s otisnutom oznakom “LILLY” i brojčanom identifikacijskom oznakom “4415”.
Elliptical, pink, coated tablets debossed with “LILLY” and a numeric identicode, “4420”.
Eliptične, ružičaste, obložene tablete s otisnutom oznakom “LILLY” i brojčanom identifikacijskom oznakom “4420”.
Elliptically shaped, white tablets imprinted with the code ’4165’.
Tablete su eliptičnog oblika, bijele boje, s otisnutom šifrom „4165“.
ELOCTA 1000 IU powder and solvent for solution for injection
ELOCTA 1000 IU prašak i otapalo za otopinu za injekciju
ELOCTA 1500 IU powder and solvent for solution for injection
ELOCTA 1500 IU prašak i otapalo za otopinu za injekciju
ELOCTA 2000 IU powder and solvent for solution for injection
ELOCTA 2000 IU prašak i otapalo za otopinu za injekciju
ELOCTA 250 IU powder and solvent for solution for injection ELOCTA 500 IU powder and solvent for solution for injection ELOCTA 750 IU powder and solvent for solution for injection ELOCTA 1000 IU powder and solvent for solution for injection ELOCTA 1500 IU powder and solvent for solution for injection ELOCTA 2000 IU powder and solvent for solution for injection ELOCTA 3000 IU powder and solvent for solution for injection
ELOCTA 250 IU prašak i otapalo za otopinu za injekciju ELOCTA 500 IU prašak i otapalo za otopinu za injekciju ELOCTA 750 IU prašak i otapalo za otopinu za injekciju ELOCTA 1000 IU prašak i otapalo za otopinu za injekciju ELOCTA 1500 IU prašak i otapalo za otopinu za injekciju ELOCTA 2000 IU prašak i otapalo za otopinu za injekciju ELOCTA 3000 IU prašak i otapalo za otopinu za injekciju
ELOCTA 250 IU powder for solution for injection
ELOCTA 250 IU prašak za otopinu za injekciju
ELOCTA 3000 IU powder and solvent for solution for injection
ELOCTA 3000 IU prašak i otapalo za otopinu za injekciju
ELOCTA 750 IU powder and solvent for solution for injection
ELOCTA 750 IU prašak i otapalo za otopinu za injekciju
Elocta can only be obtained with a prescription and treatment should be started under the supervision of a doctor who has experience in the treatment of haemophilia.
Elocta se izdaje samo na liječnički recept te liječenje mora započeti pod nadzorom liječnika s iskustvom u liječenju hemofilije.
Elocta efmoroctocog alfa
Elocta efmoroktokog alfa
Elocta is a medicine used to treat and prevent bleeding in patients with haemophilia A (an inherited bleeding disorder caused by lack of factor VIII).
Elocta je lijek koji se koristi za liječenje i sprečavanje krvarenja u bolesnika s hemofilijom A (nasljednim poremećajem krvarenja uzrokovanim manjkom faktora VIII).
Elocta is available as a powder and solvent used to make a solution for injection.
Elocta je dostupna kao prašak i otapalo koji se zajedno miješaju kako bi se dobila otopina za injekciju.
Elonva 100 micrograms injection corifollitropin alfa
Elonva 100 mikrograma injekcija korifolitropin alfa
Elonva 100 micrograms solution for injection
Elonva 100 mikrograma otopina za injekciju
Elonva 150 micrograms injection corifollitropin alfa
Elonva 150 mikrograma injekcija korifolitropin alfa
Elonva 150 micrograms solution for injection
Elonva 150 mikrograma otopina za injekciju
Elonva can only be obtained with a prescription.
Elonva se izdaje samo na liječnički recept.
Elonva corifollitropin alfa
Elonva korifolitropin alfa
Elonva is a clear and colourless aqueous solution for injection (injection) in a pre-filled syringe with an automatic safety system, which prevents needle stick injuries after use.
Elonva je bistra i bezbojna vodena otopina za injekciju (injekcija) u napunjenoj štrcaljki s automatskim sigurnosnim sustavom, koji sprječava ozljede iglom nakon uporabe.
Elonva is a solution for injection that contains the active substance corifollitropin alfa.
Elonva je otopina za injekciju koja sadrži djelatnu tvar korifolitropin alfa.
Elonva is given once as a single injection under the skin in a dose of 100 or 150 micrograms, depending on age and body weight.
Elonva se primjenjuje kao jedna injekcija pod kožu u dozi od 100 ili 150 mikrograma, ovisno o dobi i težini bolesnice.
Elonva is used in women who are undergoing fertility treatment to stimulate the development of more than one mature egg at a time in the ovaries.
Elonva se koristi u žena koje se liječi od neplodnosti, za poticanje razvoja višestrukih folikula u jajnicima.
Elonva must not be used in patients with tumours of the ovary, breast, womb, pituitary (a gland located at the base of the brain that produces FSH) or hypothalamus (a region of the brain).
Elonva se ne smije koristiti u bolesnica s tumorima jajnika, dojki, maternice, hipofize (žlijezde koja se nalazi u bazi mozga koja proizvodi FSH) ili hipotalamusa (području mozga).
Elosulfase alfa is a protein and is expected to be metabolically degraded through peptide hydrolysis.
Elosulfaza alfa je protein i očekivalo se da će se metabolički razgraditi kroz hidrolizu peptida.